Compare FSLY & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSLY | IRON |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.6B |
| IPO Year | 2019 | 2020 |
| Metric | FSLY | IRON |
|---|---|---|
| Price | $19.38 | $65.80 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | $18.00 | ★ $103.18 |
| AVG Volume (30 Days) | ★ 7.8M | 445.8K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.19 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $624,018,000.00 | N/A |
| Revenue This Year | $16.39 | N/A |
| Revenue Next Year | $10.73 | $283.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.78 | N/A |
| 52 Week Low | $6.29 | $40.00 |
| 52 Week High | $34.82 | $99.50 |
| Indicator | FSLY | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 47.47 | 42.66 |
| Support Level | $16.06 | $64.39 |
| Resistance Level | $20.27 | $65.25 |
| Average True Range (ATR) | 1.49 | 3.04 |
| MACD | 0.48 | -0.28 |
| Stochastic Oscillator | 55.20 | 13.27 |
Fastly Inc is a cloud computing company that provides an edge cloud platform designed to deliver, secure, and optimize digital experiences over the internet. The company operates a unified platform that combines content delivery, edge computing, and security capabilities. Its services include content delivery networks, web and API protection, distributed denial of service mitigation, and real-time data processing at the edge. Its platform enables customers to improve the performance, scalability, and security of applications and digital content, and also supports cloud-native architectures, AI-driven workloads, and programmable edge computing solutions.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.